Skip to main content

The biological function of tumor-derived extracellular vesicles on metabolism


Multiple studies have shown that extracellular vesicles (EVs) play a key role in the process of information transfer and material transport between cells. EVs are classified into different types according to their sizes, which includes the class of exosomes. In comparison to normal EVs, tumor-derived EVs (TDEs) have both altered components and quantities of contents. TDEs have been shown to help facilitate an environment conducive to the occurrence and development of tumor by regulation of glucose, lipids and amino acids. Furthermore, TDEs can also affect the host metabolism and immune system. EVs have been shown to have multiple clinically useful properties, including the use of TDEs as biomarkers for the early diagnosis of diseases and using the transport properties of exosomes for drug delivery. Targeting the key bioactive cargoes of exosomes could be applied to provide new strategies for the treatment of tumors. In this review, we summarize the finding of studies focused on measuring the effects of TDE on tumor-related microenvironment and systemic metabolism.

Video Abstract


In the last few years, there has been increased interest in the roles and biological functions of extracellular vesicles (EVs). Exosomes are one type of EVs and are 30-100 nm in diameter [1]. The outer membrane of exosomes is a lipid bilayer that protects the exosome contents from various stimuli in the circulating fluid. This protection allows the exosomes and its contents to achieve long-distance transport in circulating body fluids [2]. Exosomes can contain multiple soluble bioactive substances, such as DNA, RNA, metabolites, lipids and proteins. The specific contents of the exosomes are determined by the cellular source. The content of EVs can be affected by biological factors such as age, gender, and race [3]. Exosome-mediated transfer of DNA, proteins, mRNA and noncoding RNA can lead to the phenotypic change in target cells, which can induce physiological or pathological states [4].

The formation process of exosomes is thought to begin with the establishment of intraluminal vesicles (ILVs), which accumulate in the lumen and then lead to the formation of multivesicular bodies (MVBs). While a proportion of MVBs are degraded by lysosomal fusion, MVBs could also bind to the plasma membrane and could be secreted extracellularly [5]. Exosomes can be secreted into the extracellular environment by a variety of cells, including tumor cells [6], to act on local or distal target cells [7]. Endosomal sorting complex required by ESCRT (endosomal sorting complex required for transport) machinery controls the biogenesis and formation of exosomes. The ESCRT is composed of five different proteins (ESCRT-0, ESCRT-I, ESCRT-II, ESCRT-III and the AAA ATPase Vps4 complex) [8, 9]. In addition to the ESCRT mechanism, sphingolipids ceramide [10], small GTPase ADP ribosylation factor 6 (ARF6) and its effector phospholipase D2 (PLD2) [11], the tetraspanin CD63 in melanocytes [12] can also directly regulate the biogenesis and material sorting of exosomes.

Exosomes act on receptor cells in three main ways: first, proteins on the exosome membrane directly contact with proteins on the receptor cell membrane to trigger intracellular signaling cascades; second, the contents of the exosome membrane are delivered to the receptor cells after fusion with the receptor cell membrane; and third, the target cells directly engulf exosomes [13]. Uptake of exosomes is not random but depends on the interaction between recipient cells and proteins on the surface of exosomes. Some reports have shown that adhesion related molecules on exosomal surfaces determine which cells can receive exosomes. These adhesion molecules include tetraspanins, glycoproteins, and integrins [14, 15]. As a bridge for material and information transfer between cells, exosomes play a key role in local and systemic cancer cell communications. Increasing evidences have shown that exosomes play an important role in tumor proliferation, metastasis, apoptosis, and resistance to drug therapy [16, 17].

In comparison to the normal cell, the tumor cell have an increased consumption of glucose and also undergo metabolism alterations required to sustain growth and reproduction in a limited nutritional environment. Even under oxygen-rich conditions, cancer cells have a much higher rate of glycolysis than tricarboxylic acid (TCA) cycle-mediated oxidative phosphorylation (OXPHOS), a phenomenon known as the “Warburg effect” [18]. Increased glucose uptake and enhanced glycolysis, as well as high lactate production under aerobic conditions, are all considered markers of tumors. The increased demands for lipids and cholesterol in highly proliferating cancer cells also lead to changes in lipid metabolism [19]. Similarly, amino acid metabolism is increased in cancer cells, particularly in the metabolism of the major energy substrates glutamine and serine [20]. Metabolism does not exist independently but acts in concert to provide fertile soil for tumor reproduction and growth.

Studies have shown that in order to survive in the complex tumor microenvironment (TME), tumor cells increase the number of secreted exosomes to actively construct conditions suitable for their growth [21]. Tumor cells release exosomes through various regulatory mechanisms to transmit signals to other cells that trigger subsequent cancer-promoting effects, which include signals that induce invasion, metastasis, angiogenesis, or defensive effects [22]. Exosomes play a key role as a link of information and material transfer between cells in the process of tumor metabolic changes. Therefore, this review focuses on the relationship between tumor-derived exosomes and tumor metabolism, body metabolism, and their impacts on the tumorigenesis and development. It is hoped that this can provide new diagnosis and treatment ideas and strategies for tumors.

Tumor-derived exosomes

Multiple cell types, including tumor cells, can secret exosomes. The exosomes secreted by tumor cells are called tumor-derived exosomes (TDEs). Studies have estimated that the blood from cancer patients contains twice as many exosomes as the blood from healthy individuals [23]. TDE can transport information and materials not only between tumor cells, but also between stromal cells and tumor cells. Stromal cells receive exosomes from tumor cells and generate a tumor-promoting microenvironment. In turn, exosomes secreted by stromal cells act on tumor cells to promote their proliferation and invasion [24].

Selective protein sorting, controlled by posttranslational modifications, results in the enrichment of certain molecules in specific exosomes [25]. Exosomes from different cells have different characteristics. For example, adiponectin is unique to adipocyte-derived exosomes, while platelet-derived exosomes are rich in leukotrienes and prostaglandins [26]. The contents and receptors expressed by different tumor cells are also variable. For example, exosomes produced in LIM1215 (a colorectal cancer cell line) have higher level of cholesterol, sphingolipids, glycerol, and glycerolipids in comparison to other cell lines [27]. Furthermore, exosomes secreted by prostate cancer cells are rich in phosphatidylserine, high-glucose sphingomyelin, sphingomyelin, and cholesterol [28]. The presence of programmed cell death ligand 1(PD-L1) was found on exosomes isolated from the plasma of patients with non-small cell lung cancer (NSCLC), and its abundance was associated with PD-L1 positivity in tumor tissues [29]. mRNA, miRNA, DNA, and proinflammatory proteins could be enriched in TDEs from lung cancer cells, and with the transfer of these molecules, the proinflammatory phenotype of mesenchymal stem cells (MSCs) is induced and tumor cell proliferation is stimulated [30, 31].

The biogenesis and exocytosis pathways of TDEs are also regulated by specific intracellular mechanisms. The composition, function and possible targeting of exosomes are determined by modulation. Cellular and environmental signals such as inflammation, stress, or cell-cycle events could alter the specific cargo loaded into exosomes or regulate the whole process of exosome release [32]. For example, low pH and hypoxia are important features of TME, both of which promote exosome release and uptake [33, 34]. Acidic environments are best suited for the presence and sequestration of exosomes [35]. Furthermore, it has been shown that low pH can alter the lipid composition in exosome membranes, thereby enhancing exosome uptake by homologous tumor cells [34]. Pyruvate kinase M2 (PKM2) plays a key role in glucose metabolism in cancer cells, and its expression is increased under hypoxia [36]. PKM2 could promote exosome secretion by phosphorylating synaptosome associated protein 23 (SNAP-23) [37]. In summary, the secretion and transport of TDEs in TME may benefit from acidic and hypoxic microenvironment. Recently, Gurunathan et al. found that platinum nanoparticles (PtNPs) infused with lutein stimulate the release of exosomes in human lung epithelial adenoma cells (A549) by inducing oxidative stress and the ceramides pathway. The function of PtNPs to promote exosome release provides a new therapeutic target for tumor [38].

In addition to inducing tumorigenesis, TDEs may trigger a parenthetical signaling response at the site of metastasis. It has been proposed that TDEs may induce pre-metastatic niche formation, and thus enhance the progression of cancer metastasis [39]. Some studies have provided evidence that TDEs can inhibit the immune response to target tumors cells, resulting in tumor escape [40]. Furthermore, TDEs have also been found to be an important factor for the promotion of drug resistance. Studies have shown that exosomes of colorectal cancer cells can activate hepatic stellate cells to secrete IL-6. The secretion of IL-6 has been shown to regulate the lactate metabolism of hypoxic tumor cells to confer the resistance of SN38, which is the active metabolite of irinotecan [41]. Furthermore, cisplatin-resistant NSCLC cells transmit drug resistance by promoting glycolysis in sensitive cells through exosome PKM2 [42]. In conclusion, TDEs play an important role in tumor progression, immune escape and drug resistance.

The effects of exosomes on tumor metabolism

Tumor development is dependent on the surrounding environment for nutrients, which often requires the cooperation between cells in TME. TME is a highly heterogeneous and complex ecosystem incorporating both tumor and non-tumor cells. These non-tumor cells include immune and inflammatory cells, bone marrow derived cells, cancer associated fibroblasts (CAFs), adipocytes, endothelial cells and pericytes composing tumor vasculature, and the extracellular matrix (ECM) establishing a complex cross-talk with the tumor [43]. Various components affect tumor metabolism through complex interactions. Due to the remodeling nature of tumor metabolism, it is important to explore the relationship between cellular communication mediators and metabolism. In the TME, communication between cells has been shown to increase in frequency and complexity. TDEs have been shown to be important signal transmitters and are involved in the complex metabolic regulation processes of glucose and lipid metabolism (Fig. 1).

Fig. 1
figure 1

Regulation of metabolism by tumor-derived exosomes. Tumor-derived exosomes (TDEs) carrying specific substances are secreted after intracellular ESCRT machinery. TDEs act on CAFs to promote glycolysis by up-regulating GLU1 expression and down-regulating Cav1 expression. Then CAF-derived exosomes (CDEs) also act in reverse to promote glycolysis of tumor cells. TDEs could promote the polarization of TAMs towards M2 by increasing the level of oxidative phosphorylation (OXPHS) and inhibiting insulin-AKT-mTOR signal pathway of TAMs. TDEs act on MSCs to inhibit adipogenesis and promote glycolysis. TDEs act on CAAs to promote lipolysis and glycerol release. TDEs act on the pre-metastatic niche to reduce glycolysis by reducing the expression of GLU1 and PKM2 in non-tumor cells, creating a more suitable survival environment for metastasis. For the whole body, TDEs improve lipolysis, abnormal glycose metabolism and bone metabolism

Glucose metabolism

Glucose metabolism could be divided into anabolism and catabolism. Anabolism refers to the synthesis of glycogen macromolecules from monosaccharides, which requires energy consumption. After a series of decomposition reactions, glucose can release large amounts of energy to the organism. Simultaneously, intermediates formed in the decomposition process can be used as raw materials for the synthesis of biological macromolecules such as proteins, lipids and nucleic acids [18]. Glucose metabolism plays a vital role in communicating the body metabolisms and maintaining the normal life activities. Under abundant oxygen supply, normal cells direct glucose derived pyruvate to mitochondrial oxidative phosphorylation to produce ATP. However, tumor cells generally show greater glucose uptake, lysozyme flux, and lactate secretion regardless of oxygen availability [18]. Moreover, the fundamental roles of TDEs play in this biological process are intriguing.

CAFs are important components of TME. The dynamic interaction between CAFs and tumor cells plays a crucial role in tumorigenesis and progression. Tumor cells could promote glycolysis of CAFs, and alternatively, the CAFs could provide tumor cells with metabolites, such as pyruvate and lactate, through the OXPHOS and TCA cycle to fuel neighboring cancer cells. This phenomenon is known as the “Reverse Warburg Effect” [24, 44]. In fibroblasts activated by exosomes from human primary and metastatic colorectal cancer cells, caveolin-1 (Cav-1) expression was significantly down-regulated and GLUT1, the rate-limiting transporter of glucose uptake, was significantly up-regulated. Increased GLUT1 expression enhances glucose uptake and promotes glycolysis in activated fibroblasts [45]. Decreased Cav-1 expression significantly upregulates the expression of glycolytic enzymes such as lactate dehydrogenase and pyruvate kinase to promote glycolysis and promote cancer development [46]. Extracellular microRNAs (miRNAs) have recently been implicated in the intercellular crosstalk [47]. miRNA-105 in TDEs from breast cancer cells could enhance glutamine and glucose metabolism of CAFs to provide energy for neighboring tumor cells. When nutrient levels are low and metabolic by-products accumulate in the cells, CAFs are induced to overexpress the lactate transporter MCT4 (monocarboxylate transporter 4) to expel metabolic waste products lactate and β-HB from the cells. Lactate is utilized by MCT1-expressing cancer cells to increase OXPHOS levels [48, 49]. The metabolic symbiosis between CAFs and cancer cells requires that cells express the MCT1. Cancer cells induce HIF1a to create “pseudo-hypoxia” conditions for fibroblasts, and hypoxia induces calcium-dependent exosome release via MCT1 and CD147 to promote glycolysis [50, 51]. Exosomes miR-155 and miR-210 produced by melanoma are taken up by normal interstitial fibroblasts, resulting in decreased OXPHOS and increased aerobic glycolysis in fibroblasts, ultimately leading to extracellular acidification. At the same time, by inhibiting miRNA activity, exosome-mediated stromal cell metabolic reprogramming could be reversed. Matrix acidification promotes premetastatic niche formation through exosomes and promotes tumor migration and invasion [39]. Besides receiving exosomes from tumor cells, CAFs also secrete exosomes to act on cancer cells and regulate their metabolism. Uptake of CAFs derived exosomes in prostate and pancreatic cancer cells increases glutamine-dependent reductive carboxylation and glycolysis of cancer cells [52]. Through 13C metabolic flux analysis, cancer cells rapidly internalize CDEs, leading to depletion of extracellular exosomes within 24 h. Metabolites regulate glycolytic pathway flux through lactate supply and significantly alter intracellular metabolism within 24 h [53]. Thus, exosomes play an important role in the metabolic regulation interaction between tumors and CAFs.

TDE not only regulate the metabolism of CAFs, but also affect glucose metabolism of tumor-associated macrophages (TAM). Macrophages are one of the most abundant innate immune cells in TME and are associated with tumor growth, angiogenesis, metastasis, and poor prognosis. According to the surface markers of polarized macrophages and their functions, the polarized macrophages could be divided into two types: classically activated macrophages (M1) and alternatively activated macrophages (M2) [54]. The polarization of macrophage requires changes in intracellular metabolism. M1 requires less oxygen supplementation and has a high rate of glycolysis, which is conducive to survival in the hypoxic microenvironment of tumor and chronic inflammation sites. M2 is more likely to use OXPHOS and FAO (fatty acid oxidation) [55]. Jung et al. found that hypoxia-induced tumor cells could secrete more exosomes, affecting the recruitment of macrophages and promoting the polarization of M2 macrophages. This effect is achieved by TDEs that enhance oxidative phosphorylation of bone marrow-derived macrophages by transferring let-7a miRNA and inhibit the insulin-Akt-mTOR signaling pathway to affect macrophage metabolism [56]. In addition, TAMs show complex changes in metabolic patterns, including increased altered nitrogen cycling metabolism, glycolysis, and altered fatty acids synthesis, after being affected by different factors in TME [57]. These changes can induce host immunity evasion and promote tumor progression.

Tumor cells can systematically inhibit the use of nutrients by other cells to gain an advantage in growth and metastasis. For example, tumor cells secrete exosomes carrying high levels of miR-122 to inhibit glucose uptake by non-tumor cells in pre-metastatic sites [58]. Taken up by surrounding normal cells, miR-122 targets PKM2, a key mediator in the glycolytic pathway, and inhibits glycolytic metabolism, thereby reducing glucose utilization by niche non-tumor cells [58]. Metabolic remodeling of the premetastatic niche prior to the “arrival” of tumor cells has been recognized as an important means of promoting the sustained tumor progression and subsequent metastasis [59]. Fong et al. found that exosomal miR-122 secreted by breast cancer cells could inhibit glucose uptake by niche cells by down-regulating GLUT1 and PKM2. Inhibition of miR-122 in vivo can lower the glucose metabolism of distal organs such as brain and lung, and reduce the incidence of metastasis. This suggests that exosomal miR-122 can reshape whole-body energy metabolism and promote tumor progression [58].

Besides solid tumors, Wang et al. showed that exosomes secreted by acute myeloid leukemia (AML) cells, which contain VEGF/VEGFR, promote glycolysis in endothelial cells (ECs) [60]. Neovascularization provides oxygen and nutrients to tumor cells, supporting tumor development and providing a pathway for tumor metastasis. ECs in tumor vessels are more dependent on ATP produced by glycolysis than normal endothelial cells. Studies have shown that reducing high glycolysis in tumor ECs can induce therapeutic effects in preclinical tumor models [61].

Exosome mediated metabolic changes have been shown to affect the immune response to the tumor. For example, exosomes secreted by Pancreatic Ductal Adenocarcinoma (PDAC) cells which do not express SMAD can increase calcium flux and glycolysis by transferring differentially expressed proteins and miRNA associated with SMAD4. This transfer of exosomes has been shown to generate an immunosuppressive background [62]. It has been shown that overexpression of glycolytic molecules in tumor cells can impinge T-cell activation, while inhibition of glycolysis enhances T-cell-mediated antitumor immunity in vitro and in vivo [40]. Moreover, lactate, a glycolytic metabolite, has been shown to directly inhibit the cytolytic activity of NK cells and indirectly inhibit the function of NK cells by increasing the number of bone marrow derived suppressor cells (MDSCs) [63]. These findings suggest that immune suppression induced by metabolic recoding mediated by TDEs may be a potential trigger for tumor development.

Lipid metabolism

Exosome-mediated disruption of lipid metabolism is increasingly recognized as a feature of tumor cells and may be a key factor in the progression and metastatic behavior of malignant tumors [64]. Studies have shown that lipid metabolism disorders can upregulate oncogenes such as Mtor, cyclin-E, c-Jun, Notch, c-Myb, and c-Myc to promote tumor invasion and metastasis [65]. Exosome membranes contain many molecules which may include phosphatidic acid (PA), phosphatidyl inositol (PI), phosphatidyl ethanolamine (PE), phosphatidyl choline (PC), phosphatidyl serine (PS), ceramide, cholesterol, sphingomyelin, glycosphingomyelin, and other lipids in low abundance. Some have suggested that PS and PE appear to be involved in the biogenesis of exosomes [66]. The enrichment of specific lipids has been shown to significantly increased exosome membrane hardness. Moreover, these lipids exist in the outer membrane of exosomes and play a crucial role in the recognition and internalization of exosomes, enabling them to deliver metabolites to recipient cell [67]. Depletion of a cholesterol lipid efflux pump ABCG1 (ATP-binding cassette transporter G1), leads to the accumulation of EVs and their derivatives, thereby triggering tumor regression [68]. Tafelmeier et al. have demonstrated that ABCG1-mediated cholesterol efflux promotes exosome release, while SRB1-mediated cholesterol efflux inhibits exosome uptake by recipient cells [69].

The role of lipids in cell communication is an interesting emerging topic of research and is worth further investigation. Exosomes are known to carry bioactive lipids, such as prostaglandins and leukotrienes, which have been shown to promote the development of tumors [70]. Furthermore, Lydic et al. found that TDEs from colorectal cancer cell line LIM1215 have higher levels of glycerolipids, cholesterol, glycerol, and sphingolipids [27]. Others have shown that TDEs from prostate cancer cells are rich in phosphatidylserine, glycosphingolipids, sphingomyelin, and cholesterol [28]. High fat content appears to be more conducive to the uptake of TDEs by normal cells, inducing the transformation of normal cells into tumor cells [65, 71, 72].

It has been shown that tumor derived signaling molecules trigger lipolysis in cancer-associated adipocytes (CAAs), which results in lipoatrophy in humans [73], a form of cancer cachexia [74]. Phospho-hormone-sensitive lipase (P-HSL), a marker that activates lipolysis, was found at higher levels in TDEs from Lewis lung Cancer (LLC). Adipocytes exposed to TDEs from LLC showed lower levels of lipid droplets and higher levels of glycerol release [75]. Another study showed that TDEs from pancreatic cancer cells containing adrenomedullin (AM) interact with adrenomedullin receptors (ADMRs) in adipocytes and activate ERK 1/2 and MAPKs p38 signaling pathways to induce lipolysis via HSL phosphorylation [76]. Wang et al. found that TDEs from lung cancer could be internalized by human adipose tissue-derived MSCs and participate in the inhibition of adipogenesis of MSCs through TGFβ signaling pathway [77]. The effect between the two is reciprocal, TDEs regulate the metabolism of MSCs, and MSCs affected by TDEs secrete more exosomes as a kind of feedback to promote tumor angiogenesis [78]. Whether MSC-derived EVs promote or inhibit cancer seems to depend on the contents of cytokines and miRNA in exosomes [79,80,81]. Interestingly, lipids carried in exosomes have also been found to be important for inducing tumor drug resistance. For example, through regulating lipid metabolism, studies have shown that high expression of acid sphingomyelinase (ASM) by multiple myeloma (MM) derived exosomes can transfer drug-resistant phenotypes to drug-sensitive MM cells. The expression and protein level of ASM in MM cells and exosomes increased after antitumor drug stimulation, reflecting the tumor protective effect of ASM and promoting the occurrence of drug resistance [82].

Lipids in TDEs have also been shown to alter immune responses. For example, Jiang et al. found that overexpression of FASN (Fatty Acid Synthase) in ovarian cancer led to lipid accumulation in TME, resulting in T cell dysfunction, and then impaired anti-tumor immune responses [83]. It has also been shown that high cholesterol is more conducive for exosomes to bind to CD8 ( +) T cells, as the enrichment of cholesterol in cell membranes can improve the fluidity of cell membranes [84].

Amino acid metabolism and nucleotide metabolism

Studies on exosomes and amino acid metabolism mainly focus on tumor cells and CAFs and provides evidence that TDEs could induce CAFs production [85]. Liu et al. found that CAFs mainly regulated amino acid metabolism in an exosome-dependent manner in lung adenocarcinoma (LUAD) cells. Stimulated by tumor-derived proinflammatory cytokines, the specific long noncoding RNA LINC01614 secreted from CAFs, was up-regulated. CAF-derived exosomes could promote NF-κB activation through transport of LINC01614 to LUAD cells, which then interacted with ANXA2 and p65, leading to upregulation of glutamine transporters SLC7A5 and SLC38A2. Ultimately, LINC01614 enhanced glutamine uptake in LUAD cells [86]. Moreover, Zhao et al. found that exosomes secreted by CAFs could significantly inhibit electron transport chains after being absorbed by prostate and pancreatic cancer cells, thus increasing glutamine dependent reduction carboxylation [52]. The above studies suggest that exosomes play a key role in regulating the metabolism of glutamine. Furthermore, because glutamine is a nitrogen donor for nucleotide synthesis [87] TDEs effects on glutamine is likely to also affect nucleotide synthesis. Therefore, it could be speculated that TDEs may regulate the generation and degradation of nucleic acids by reacting to nucleotide metabolites and metabolic wastes. While the effects of TDEs on nucleotide metabolism is interesting, the current understanding about this biology is limited and further studies are warranted.

Effects on systemic metabolism

The normal state of the body is one of equilibrium and homeostasis. The development of neoplasms can upset this balance, for example emaciation is considered to be a manifestation of tumor cachexia. It has been shown that TDEs from pancreatic cancer could induce subcutaneous adipose tissue lipolysis through AM as a mediator, suggesting that TDEs induced lipolysis may be associated with weight loss in patients [76]. In addition, Fong et al. found that inhibition of exosomal miR-122 could normalize glucose metabolism of the brain, lung and other distal organs and reduce the incidence of tumor metastasis, indicating that exosomal miR-122 could reshape the whole body energy metabolism and promote tumor progression [58]. It has been found that TDEs from prostate cancer (PCa) containing PKM2 could be transferred to bone marrow stromal cells (BMSCs) and promote tumor metastasis by altering bone metabolism [88]. And It has been found that TDEs from PCa transfer LncRNA nuclear-enriched abundant transcript 1 (NEAT1) to human bone marrow-derived MSCs promote osteogenic differentiation, suggesting that this might be one of the reasons why patients with PCa often present with osteoblast bone metastases [89]. In summary, TDEs have been shown to have significant effects on the whole-body metabolism, although the whole-body metabolism is complex, and requires further exploration.

Recent studies have found that metabolism alterations caused by TDEs can affect the immune system which can aid in the ability of the tumor to escape the immune system. Studies have shown that TDEs can lead to increased glucose uptake by macrophages in the pre-metastasis niche through TLR2 and NF-κB signaling pathways, thus increasing the expression of PD-L1 and promoting the polarization of macrophages towards immunosuppressive phenotypes [90]. In addition, TDEs activate Tregs cells to form immunotolerant premetastatic niches by regulating the interaction of CCL1 + fibroblasts and CCR8 + Treg cells [91]. This provides immune conditions for tumor metastasis. Peroxisome proliferator activated receptor (PPAR) α response to fatty acids delivered by TDEs and leads to excess lipid droplet formation and enhanced fatty acid oxidation, ultimately leading to metabolic shift to mitochondrial oxidative phosphorylation, which drives dendritic cell immune dysfunction [92]. In summary, multiple studies have shown that TDEs mediated metabolism alterations can cause deleterious effects for the ability of the immune system to target tumor cells.


Diagnostic biomarkers

A large number of tumor markers carried by cancer cell exosomes have set off a boom in liquid biopsy. The application of TDEs was shown in Fig. 2. Depending on the chemical, physical, and biological properties of exosomes, different methods have been used to isolate and purify exosomes, including ultra-centrifugation, size exclusion chromatography, ultrafiltration, and microplate-based magnetic immunocapture. Using multiple techniques based on membrane protein composition, size and density, rich exosome populations could be isolated from the various biological fluids and cell media [93]. The liquid biopsy strategy assesses factors including circulating tumor cells, circulating tumor DNA (ctDNA), EVs or exosomes, and other biochemical substances [94,95,96]. Since exosomes are detectable in almost all body fluids, they are more readily available, making them ideal biomarkers for monitoring dynamic intratumoral heterogeneity (ITH), enabling early detection and minimizing treatment side effects and toxicity [22, 97]. There has been a growing number of clinical trials related to exosomes in multiple cancer types, a summary of these trials are shown in Table 1.

Fig. 2
figure 2

The application of tumor-derived exosomes (TDEs). The application of tumor-derived exosomes (TDEs) is mainly divided into two kinds: as a biomarker for diagnosis and participating in treatment. Starting from the diagnostic biomarkers, the biomarkers related to diagnosis or prognosis should be determined first, and then the isolated and purified exosomes can be obtained by centrifugation, filtration and other methods, and substances required for detection in the exosomes can be detected to help diagnosis and treatment. From the perspective of treatment, the tumor-promoting function can be blocked by inhibiting the release of TDEs or inhibiting the absorption of TDEs by other cells. TDEs could also be used to load drugs or prepare tumor vaccines

Table 1 Ongoing clinical trials of exosomes in cancer diseases

Although the development of science and technology for exosome detection is growing, there are still many problems to be solved. First, each exosome assay technique is known to have its own bias in estimating exosome size. For example, Nanoparticle Tracking Analysis (NTA) is widely used for exosome size detection in bioparticle applications, and its detection limit for bioparticles is about 70 nm. NTA and Transmission Electron Microscopy are sensitive to different sizes [98]. Moreover, the process of exosome preparation may result in swelling, shrinkage, or obesity of the exosome, and these changes have a significant impact on true size analysis [66]. In addition, due to technical limitations, it is not possible to obtain fully purified exosomes, which also affects the accuracy of EV analysis. For example, EVs in the typical exosome size range are known to include exosomes (20—100 nm), microvesicles (100–1000 nm) and apoptotic bodies (1–5 μm), VLDL, chylomicrons, and retroviruses cannot be effectively separated from exosomes completely by centrifugation because of their similar membrane orientation and density [99]. Furthermore, Exosome size may vary considerably even within the same single cell line, perhaps due to the inhomogeneous invagination inherent in the restrictive membrane during exosome biogenesis [66]. Interestingly, exosome size has been reported to be related with certain diseases. For example, in patients with NSCLC, tumor-draining pulmonary vein blood secrete body size (< 112 nm) is associated with a shorter time to recurrence and shorter overall survival [100].

The exosome population is made up of exosomes of different internal and external carriers, different sizes, different cellular origins, different functional effects on the recipient cell, and resulting in uneven application functions [66]. The content of exosomes reflects the state of secretory cells to some extent, making them potentially useful for assessing normal and pathophysiological status [3, 101].

Recent studies have shown that exosomes can be used as biomarkers to diagnose, identify the stage and the subtype of tumor cells. In 2015, Dr. Raghu Kallur’s team found that GPC1 protein contained in exosomes of pancreatic cancer cells could be used as a non-invasive method to diagnose and screen early pancreatic cancer at a stage suitable for surgical treatment. Most importantly, it can distinguish chronic pancreatitis from early or advanced pancreatic cancer, providing a new approach to the diagnosis of early pancreatic cancer, which is difficult to detect clinically [102]. Moreover, through the bone marrow, PCa cells create a pre-metastatic niche through primary PCa TDEs mediated PKM2 transfer to BMSCs and subsequent CXCL12 upregulation. This novel mechanism suggests that exosomal PKM2 may serve as a therapeutic biomarker target for PCa bone metastases [88]. Furthermore, Roberg-Larsen et al. showed the TDEs from MCF-7 cell line (estrogen receptor (ER +) breast cancer cell line) had increased levels of 27-OHC in compared with TDEs from the ER- breast cancer cell line (MDA-MB-231), providing evidence that TDEs may contain additional information of diagnostic value [103].

Exosomes are stable sources of miRNA in body fluids, which prevent the degradation of biomacromolecules under fluctuating body conditions [104]. These highly stabile miRNAs in exosomes are attractive non-invasive biomarker targets for cancer screening and disease surveillance. Analysis of exosome miRNAs in the sera of healthy individuals and cancer patients revealed important differences related to tumor progression, while highlighting the potential value of these miRNAs as biomarkers of disease prognosis [105]. miRNA detected in serum TDEs from breast cancer patients can be used to discriminate between specific molecular subtypes. Furthermore, it has been found that high level of miR-373 in TDEs from breast cancer correlates with triple-negative or other highly aggressive breast cancer types, highlighting the potential role of serum-specific exosomal miR-373 as an aggressive tumor biomarker [106]. The identification of in vitro miRNAs that associate with tumor metastases could provide an additional diagnostic tool to assess disease stage and monitor its progression. High levels of miR-105 have been found in serum-derived exosomes from breast cancer patients who later develop metastatic disease [107]. Similarly, down-regulation of miR-19a and/or miR-29c and up-regulation of miR-210 have been detected in TDEs from brain metastatic breast cancer cells [108]. The overexpression of miR-483-3p occurs in the early development of PDAC and exists in precancerous PanIN lesions, providing evidence that miR-483-3p might be a biomarker for early diagnosis and prognosis of PDAC [109].


One interesting therapeutic idea involves harnessing the functionality of exosomes, which transport proteins, lipids, and nucleic acids to mediate cell-to-cell communication between TMEs components, for anticancer therapy. Therefore, research focused on targeting exosome biogenesis and loading is required before the exosome could be used as a viable strategy to treat cancers.

Recent studies have investigated if manipulating the release of TDEs could be used for therapeutics. Inhibition of Rab27 with targeted shRNAs has been shown to reduce exosome release, but this manipulation also leads to a significant increase in smaller endosome-sized vesicles (50 nm), implying that Rab proteins have the ability to alter the size distribution of exosomes [110]. Others have shown that GW4869 (exosome-release inhibitor) can block the secretion of exosomes and reverse metabolic changes in breast cancer cells. GW4869 inhibits glycolysis and receptor cell activation in tumor cells, thereby inhibiting cancer progression [111, 112]. Fanny et al. found that reducing exosomes production with dimethyl amiloride enhanced the antitumor efficacy of the chemotherapy drug cyclophosphamide in vivo in three different mouse tumor models [113]. Another possible mechanism to inhibit the tumor-promoting function of TDEs is to prevent exosome fusion or uptake by target cells. One study suggested that TDEs uptake by cells could be prevented by targeting specific exosome biomarkers [114]. For example, a recent study showed that positively charged mesoporous silica nanoparticles (MSNs) with EGFR-targeting aptamers (MSN-AP) could interact and eliminate circulating cancer-derived negatively charged exosomes by allowing them to enter the small intestine, thereby reducing metastasis formation [115].

Exosomes have also been used to build cancer vaccines. For example, Huang et al. loaded Hiltonol (TLR3 agonist) and the immunogenic cell death inducers human neutrophil elastase into α-LA (α-lactalbumin)-engineered breast cancer-derived exosomes to form an in situ DC vaccine (HELA-Exos). HELA-Exos has been shown to exhibit potent antitumor activity in both mouse models and human breast cancer organoids, which improves subsequent tumor-reactive CD8 + T-cell response by promoting the activation of type one conventional dendritic cells in situ [116]. Taking advantage of the property that TDEs can specifically deliver drugs to the tumor site, Zhu et al. found that TDEs could be developed for combined delivery of AIEgen and proton pump inhibitors (PPI) for the combined treatment of gastric cancer [117]. In addition, a recent study found successful evaluation of drug efficacy by using exosome-synthesized probes to detect drug occupancy [118]. While the early studies of exosome cancer vaccines are promising, more researches are needed to determine the feasibility of antitumor exosome for use in human and mass production. In addition to using cell exosomes, artificial engineering such as freeze–thaw cycles, electroporation, ultrasound, reagent transfection, or saponin methods, are also methods for loading drugs or functional cargo into exosomes [119]. Hypoxia might influence the suitability of exosome cargo as a scaffold for fusion of functional molecules and other drugs, thus affecting the efficiency of treatment. In addition, exosomes in TME exhibit specific uptake under hypoxic conditions, which might provide a pathway for specific targeting of malignant tumors [22].

Conclusion and prospects

Tumor-derived exosomes play a key role in the development of tumors. By regulating the glucose and lipid metabolism of tumor cells and other cells in TME, TDEs promotes more suitable soil and materials for tumor growth. From this point of view, many researchers hope to provide new strategies for the diagnosis and treatment of cancer patients by improving the technology of exosomes detection and isolation, inhibiting the secretion of TDEs, or blocking the binding of TDEs with targeted cells. However, there are also problems that need attention, including how to quickly and effectively load drugs into exosomes, how to enhance the stability, and how to improve the specificity and targeting. It is believed that in the near future, with the progress of science and technology and the continuous efforts of researchers, these questions will get addressed, providing new benefits to patients.

Availability of data and materials

Not applicable.



Extracellular vesicles


Tumor-derived EVs


Intraluminal vesicles


Multivesicular bodies


Endosomal sorting complex required for transport


ADP ribosylation factor 6


Phospholipase D2


Tricarboxylic acid cycle


Oxidative phosphorylation


Tumor microenvironment


Non-small cell lung cancer


Mesenchymal stem cells


Pyruvate kinase M2


Synaptosome associated protein 23


Platinum nanoparticles


Cancer associated fibroblasts


Extracellular matrix




Monocarboxylate transporter 4


Tumor-associated macrophages


Fatty acid oxidation


Endothelial cells


Pancreatic Ductal Adenocarcinoma


Marrow derived suppressor cells


Phosphatidic acid


Phosphatidyl inositol


Phosphatidyl ethanolamine


Phosphatidyl choline


Phosphatidyl serine


ATP-binding cassette transporter G1


Cancer-associated adipocytes


Phospho-hormone-sensitive lipase


Adrenomedullin receptors


Acid sphingomyelinase


Fatty Acid Synthase


Lung adenocarcinoma


Prostate cancer


Bone marrow stromal cells


Nuclear-enriched abundant transcript 1


Circulating tumor DNA


Intratumoral heterogeneity


Nanoparticle Tracking Analysis


Mesoporous silica nanoparticles with EGFR-targeting aptamers


  1. Hoshino A, Costa-Silva B, Shen TL, et al. Tumour exosome integrins determine organotropic metastasis. Nature. 2015;527(7578):329–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Wang W, Zhu N, Yan T, et al. The crosstalk: exosomes and lipid metabolism. Cell Commun Signal. 2020;18(1):119.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Noren Hooten N, Byappanahalli AM, Vannoy M, Omoniyi V, Evans MK. Influences of age, race, and sex on extracellular vesicle characteristics. Theranostics. 2022;12(9):4459–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Ma P, Pan Y, Li W, et al. Extracellular vesicles-mediated noncoding RNAs transfer in cancer. J Hematol Oncol. 2017;10(1):57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Thery C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002;2(8):569–79.

    Article  CAS  PubMed  Google Scholar 

  6. Colombo M, Raposo G, Thery C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014;30:255–89.

    Article  CAS  PubMed  Google Scholar 

  7. Milane L, Singh A, Mattheolabakis G, Suresh M, Amiji MM. Exosome mediated communication within the tumor microenvironment. J Control Release. 2015;219:278–94.

    Article  CAS  PubMed  Google Scholar 

  8. Hurley JH. The ESCRT complexes. Crit Rev Biochem Mol Biol. 2010;45(6):463–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Katzmann DJ, Babst M, Emr SD. Ubiquitin-dependent sorting into the multivesicular body pathway requires the function of a conserved endosomal protein sorting complex. ESCRT-I Cell. 2001;106(2):145–55.

    Article  CAS  PubMed  Google Scholar 

  10. Trajkovic K, Hsu C, Chiantia S, et al. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science. 2008;319(5867):1244–7.

    Article  CAS  PubMed  Google Scholar 

  11. Ghossoub R, Lembo F, Rubio A, et al. Syntenin-ALIX exosome biogenesis and budding into multivesicular bodies are controlled by ARF6 and PLD2. Nat Commun. 2014;5:3477.

    Article  CAS  PubMed  Google Scholar 

  12. van Niel G, Charrin S, Simoes S, et al. The tetraspanin CD63 regulates ESCRT-independent and -dependent endosomal sorting during melanogenesis. Dev Cell. 2011;21(4):708–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Barros FM, Carneiro F, Machado JC, Melo SA. Exosomes and Immune response in Cancer: friends or foes? Front Immunol. 2018;9:730.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Rana S, Yue S, Stadel D, Zoller M. Toward tailored exosomes: the exosomal tetraspanin web contributes to target cell selection. Int J Biochem Cell Biol. 2012;44(9):1574–84.

    Article  CAS  PubMed  Google Scholar 

  15. Nazarenko I, Rana S, Baumann A, et al. Cell surface tetraspanin Tspan8 contributes to molecular pathways of exosome-induced endothelial cell activation. Cancer Res. 2010;70(4):1668–78.

    Article  CAS  PubMed  Google Scholar 

  16. Zhang L, Yu D. Exosomes in cancer development, metastasis, and immunity. Biochim Biophys Acta Rev Cancer. 2019;1871(2):455–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Milman N, Ginini L, Gil Z. Exosomes and their role in tumorigenesis and anticancer drug resistance. Drug Resist Updat. 2019;45:1–12.

    Article  PubMed  Google Scholar 

  18. Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309–14.

    Article  CAS  PubMed  Google Scholar 

  19. Currie E, Schulze A, Zechner R, Walther TC, Farese RV Jr. Cellular fatty acid metabolism and cancer. Cell Metab. 2013;18(2):153–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Hensley CT, Wasti AT, DeBerardinis RJ. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest. 2013;123(9):3678–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Rodriguez M, Silva J, Lopez-Alfonso A, et al. Different exosome cargo from plasma/bronchoalveolar lavage in non-small-cell lung cancer. Genes Chromosomes Cancer. 2014;53(9):713–24.

    Article  CAS  PubMed  Google Scholar 

  22. He G, Peng X, Wei S, et al. Exosomes in the hypoxic TME: from release, uptake and biofunctions to clinical applications. Mol Cancer. 2022;21(1):19.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Kalluri R. The biology and function of exosomes in cancer. J Clin Invest. 2016;126(4):1208–15.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Tan S, Xia L, Yi P, et al. Exosomal miRNAs in tumor microenvironment. J Exp Clin Cancer Res. 2020;39(1):67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Carnino JM, Ni K, Jin Y. Post-translational modification regulates formation and cargo-loading of extracellular vesicles. Front Immunol. 2020;11:948.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Phoonsawat W, Aoki-Yoshida A, Tsuruta T, Sonoyama K. Adiponectin is partially associated with exosomes in mouse serum. Biochem Biophys Res Commun. 2014;448(3):261–6.

    Article  CAS  PubMed  Google Scholar 

  27. Lydic TA, Townsend S, Adda CG, Collins C, Mathivanan S, Reid GE. Rapid and comprehensive ‘shotgun’ lipidome profiling of colorectal cancer cell derived exosomes. Methods. 2015;87:83–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Llorente A, Skotland T, Sylvanne T, et al. Molecular lipidomics of exosomes released by PC-3 prostate cancer cells. Biochim Biophys Acta. 2013;1831(7):1302–9.

    Article  CAS  PubMed  Google Scholar 

  29. Kim DH, Kim H, Choi YJ, et al. Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer. Exp Mol Med. 2019;51(8):1–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Rahman MA, Barger JF, Lovat F, Gao M, Otterson GA, Nana-Sinkam P. Lung cancer exosomes as drivers of epithelial mesenchymal transition. Oncotarget. 2016;7(34):54852–66.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Li X, Wang S, Zhu R, Li H, Han Q, Zhao RC. Lung tumor exosomes induce a pro-inflammatory phenotype in mesenchymal stem cells via NFkappaB-TLR signaling pathway. J Hematol Oncol. 2016;9:42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Gurunathan S, Kang MH, Kim JH. A comprehensive review on factors influences biogenesis, functions, therapeutic and clinical implications of exosomes. Int J Nanomedicine. 2021;16:1281–312.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Villarroya-Beltri C, Baixauli F, Gutierrez-Vazquez C, Sanchez-Madrid F, Mittelbrunn M. Sorting it out: regulation of exosome loading. Semin Cancer Biol. 2014;28:3–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Gong C, Zhang X, Shi M, et al. Tumor exosomes reprogrammed by low pH are efficient targeting vehicles for smart drug delivery and personalized therapy against their homologous tumor. Adv Sci (Weinh). 2021;8(10):2002787.

    Article  CAS  PubMed  Google Scholar 

  35. Ban JJ, Lee M, Im W, Kim M. Low pH increases the yield of exosome isolation. Biochem Biophys Res Commun. 2015;461(1):76–9.

    Article  CAS  PubMed  Google Scholar 

  36. Luo W, Hu H, Chang R, et al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell. 2011;145(5):732–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Wei Y, Wang D, Jin F, et al. Pyruvate kinase type M2 promotes tumour cell exosome release via phosphorylating synaptosome-associated protein 23. Nat Commun. 2017;8:14041.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Gurunathan S, Kang MH, Jeyaraj M, Kim JH. Platinum nanoparticles enhance exosome release in human lung epithelial adenocarcinoma cancer cells (A549): oxidative stress and the ceramide pathway are key players. Int J Nanomedicine. 2021;16:515–38.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Shu S, Yang Y, Allen CL, et al. Metabolic reprogramming of stromal fibroblasts by melanoma exosome microRNA favours a pre-metastatic microenvironment. Sci Rep. 2018;8(1):12905.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Cascone T, Mckenzie JA, Mbofung RM, et al. Increased tumor glycolysis characterizes immune resistance to adoptive t cell therapy. Cell Metab. 2018;27(5):977-987 e4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Li F, Zhan L, Dong Q, et al. Tumor-derived exosome-educated hepatic stellate cells regulate lactate metabolism of hypoxic colorectal tumor cells via the IL-6/STAT3 pathway to confer drug resistance. Onco Targets Ther. 2020;13:7851–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Wang D, Zhao C, Xu F, et al. Cisplatin-resistant NSCLC cells induced by hypoxia transmit resistance to sensitive cells through exosomal PKM2. Theranostics. 2021;11(6):2860–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Belli C, Trapani D, Viale G, et al. Targeting the microenvironment in solid tumors. Cancer Treat Rev. 2018;65:22–32.

    Article  CAS  PubMed  Google Scholar 

  44. Martinez-Outschoorn UE, Pavlides S, Howell A, et al. Stromal-epithelial metabolic coupling in cancer: integrating autophagy and metabolism in the tumor microenvironment. Int J Biochem Cell Biol. 2011;43(7):1045–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Rai A, Greening DW, Chen M, Xu R, Ji H, Simpson RJ. Exosomes derived from human primary and metastatic colorectal cancer cells contribute to functional heterogeneity of activated fibroblasts by reprogramming their proteome. Proteomics. 2019;19(8):e1800148.

    Article  CAS  PubMed  Google Scholar 

  46. Sotgia F, Martinez-Outschoorn UE, Howell A, Pestell RG, Pavlides S, Lisanti MP. Caveolin-1 and cancer metabolism in the tumor microenvironment: markers, models, and mechanisms. Annu Rev Pathol. 2012;7:423–67.

    Article  CAS  PubMed  Google Scholar 

  47. Zhuang G, Wu X, Jiang Z, et al. Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. EMBO J. 2012;31(17):3513–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Yan W, Wu X, Zhou W, et al. Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells. Nat Cell Biol. 2018;20(5):597–609.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Hong CS, Graham NA, Gu W, et al. MCT1 Modulates Cancer cell pyruvate export and growth of tumors that co-express MCT1 and MCT4. Cell Rep. 2016;14(7):1590–601.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Pertega-Gomes N, Felisbino S, Massie CE, et al. A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy. J Pathol. 2015;236(4):517–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Thakur A, Qiu G, Xu C, et al. Label-free sensing of exosomal MCT1 and CD147 for tracking metabolic reprogramming and malignant progression in glioma. Sci Adv. 2020;6(26):eaaz6119.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Zhao H, Yang L, Baddour J, et al. Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism. Elife. 2016;5:e10250.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Achreja A, Zhao H, Yang L, Yun TH, Marini J, Nagrath D. Exo-MFA - A 13C metabolic flux analysis framework to dissect tumor microenvironment-secreted exosome contributions towards cancer cell metabolism. Metab Eng. 2017;43(Pt B):156–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Rabold K, Netea MG, Adema GJ, Netea-Maier RT. Cellular metabolism of tumor-associated macrophages - functional impact and consequences. FEBS Lett. 2017;591(19):3022–41.

    Article  CAS  PubMed  Google Scholar 

  55. Zhu L, Zhao Q, Yang T, Ding W, Zhao Y. Cellular metabolism and macrophage functional polarization. Int Rev Immunol. 2015;34(1):82–100.

    Article  CAS  PubMed  Google Scholar 

  56. Park JE, Dutta B, Tse SW, et al. Hypoxia-induced tumor exosomes promote M2-like macrophage polarization of infiltrating myeloid cells and microRNA-mediated metabolic shift. Oncogene. 2019;38(26):5158–73.

    Article  CAS  PubMed  Google Scholar 

  57. Netea-Maier RT, Smit JWA, Netea MG. Metabolic changes in tumor cells and tumor-associated macrophages: a mutual relationship. Cancer Lett. 2018;413:102–9.

    Article  CAS  PubMed  Google Scholar 

  58. Fong MY, Zhou W, Liu L, et al. Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nat Cell Biol. 2015;17(2):183–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Peinado H, Lavotshkin S, Lyden D. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin Cancer Biol. 2011;21(2):139–46.

    Article  CAS  PubMed  Google Scholar 

  60. Wang B, Wang X, Hou D, et al. Exosomes derived from acute myeloid leukemia cells promote chemoresistance by enhancing glycolysis-mediated vascular remodeling. J Cell Physiol. 2019;234(7):10602–14.

    Article  CAS  PubMed  Google Scholar 

  61. Rohlenova K, Veys K, Miranda-Santos I, De Bock K, Carmeliet P. Endothelial cell metabolism in health and disease. Trends Cell Biol. 2018;28(3):224–36.

    Article  CAS  PubMed  Google Scholar 

  62. Basso D, Gnatta E, Padoan A, et al. PDAC-derived exosomes enrich the microenvironment in MDSCs in a SMAD4-dependent manner through a new calcium related axis. Oncotarget. 2017;8(49):84928–44.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Husain Z, Huang Y, Seth P, Sukhatme VP. Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells. J Immunol. 2013;191(3):1486–95.

    Article  CAS  PubMed  Google Scholar 

  64. Luo X, Zhao X, Cheng C, Li N, Liu Y, Cao Y. The implications of signaling lipids in cancer metastasis. Exp Mol Med. 2018;50(9):1–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Liu Z, Liu X, Liu S, Cao Q. Cholesterol promotes the migration and invasion of renal carcinoma cells by regulating the KLF5/miR-27a/FBXW7 pathway. Biochem Biophys Res Commun. 2018;502(1):69–75.

    Article  CAS  PubMed  Google Scholar 

  66. Pegtel DM, Gould SJ. Exosomes. Annu Rev Biochem. 2019;88:487–514.

    Article  CAS  PubMed  Google Scholar 

  67. Zakharova L, Svetlova M, Fomina AF. T cell exosomes induce cholesterol accumulation in human monocytes via phosphatidylserine receptor. J Cell Physiol. 2007;212(1):174–81.

    Article  CAS  PubMed  Google Scholar 

  68. Namba Y, Sogawa C, Okusha Y, et al. Depletion of lipid efflux pump abcg1 triggers the intracellular accumulation of extracellular vesicles and reduces aggregation and tumorigenesis of metastatic Cancer cells. Front Oncol. 2018;8:376.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Tafelmeier M, Fischer A, Orso E, et al. Mildly oxidized HDL decrease agonist-induced platelet aggregation and release of pro-coagulant platelet extracellular vesicles. J Steroid Biochem Mol Biol. 2017;169:176–88.

    Article  CAS  PubMed  Google Scholar 

  70. Xiang X, Poliakov A, Liu C, et al. Induction of myeloid-derived suppressor cells by tumor exosomes. Int J Cancer. 2009;124(11):2621–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Wu B, Cui J, Yang XM, et al. Cytoplasmic fragment of CD147 generated by regulated intramembrane proteolysis contributes to HCC by promoting autophagy. Cell Death Dis. 2017;8(7):e2925.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Hosseini-Beheshti E, Choi W, Weiswald LB, et al. Exosomes confer pro-survival signals to alter the phenotype of prostate cells in their surrounding environment. Oncotarget. 2016;7(12):14639–58.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Cao Y. Adipocyte and lipid metabolism in cancer drug resistance. J Clin Invest. 2019;129(8):3006–17.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Argiles JM, Busquets S, Stemmler B, Lopez-Soriano FJ. Cancer cachexia: understanding the molecular basis. Nat Rev Cancer. 2014;14(11):754–62.

    Article  CAS  PubMed  Google Scholar 

  75. Hu W, Ru Z, Xiao W, et al. Adipose tissue browning in cancer-associated cachexia can be attenuated by inhibition of exosome generation. Biochem Biophys Res Commun. 2018;506(1):122–9.

    Article  CAS  PubMed  Google Scholar 

  76. Sagar G, Sah RP, Javeed N, et al. Pathogenesis of pancreatic cancer exosome-induced lipolysis in adipose tissue. Gut. 2016;65(7):1165–74.

    Article  CAS  PubMed  Google Scholar 

  77. Wang S, Li X, Xu M, Wang J, Zhao RC. Reduced adipogenesis after lung tumor exosomes priming in human mesenchymal stem cells via TGFbeta signaling pathway. Mol Cell Biochem. 2017;435(1–2):59–66.

    Article  CAS  PubMed  Google Scholar 

  78. Dostert G, Mesure B, Menu P, Velot E. How do mesenchymal stem cells influence or are influenced by microenvironment through extracellular vesicles communication? Front Cell Dev Biol. 2017;5:6.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Lopatina T, Gai C, Deregibus MC, Kholia S, Camussi G. Cross talk between cancer and mesenchymal stem cells through extracellular vesicles carrying nucleic acids. Front Oncol. 2016;6:125.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Lee JK, Park SR, Jung BK, et al. Exosomes derived from mesenchymal stem cells suppress angiogenesis by down-regulating VEGF expression in breast cancer cells. PLoS One. 2013;8(12):e84256.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Shi S, Zhang Q, Xia Y, et al. Mesenchymal stem cell-derived exosomes facilitate nasopharyngeal carcinoma progression. Am J Cancer Res. 2016;6(2):459–72.

    CAS  PubMed  PubMed Central  Google Scholar 

  82. Faict S, Oudaert I, D’Auria L, et al. The transfer of sphingomyelinase contributes to drug resistance in multiple Myeloma. Cancers (Basel). 2019;11(12):1823.

    Article  CAS  PubMed  Google Scholar 

  83. Jiang L, Fang X, Wang H, Li D, Wang X. Ovarian Cancer-Intrinsic fatty acid synthase prevents anti-tumor immunity by disrupting tumor-infiltrating dendritic cells. Front Immunol. 2018;9:2927.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Yang W, Bai Y, Xiong Y, et al. Potentiating the antitumour response of CD8(+) T cells by modulating cholesterol metabolism. Nature. 2016;531(7596):651–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Yeon JH, Jeong HE, Seo H, et al. Cancer-derived exosomes trigger endothelial to mesenchymal transition followed by the induction of cancer-associated fibroblasts. Acta Biomater. 2018;76:146–53.

    Article  CAS  PubMed  Google Scholar 

  86. Liu T, Han C, Fang P, et al. Cancer-associated fibroblast-specific lncRNA LINC01614 enhances glutamine uptake in lung adenocarcinoma. J Hematol Oncol. 2022;15(1):141.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Hosios AM, Hecht VC, Danai LV, et al. Amino acids rather than glucose account for the majority of cell mass in proliferating mammalian cells. Dev Cell. 2016;36(5):540–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Dai J, Escara-Wilke J, Keller JM, et al. Primary prostate cancer educates bone stroma through exosomal pyruvate kinase M2 to promote bone metastasis. J Exp Med. 2019;216(12):2883–99.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Mo C, Huang B, Zhuang J, Jiang S, Guo S, Mao X. Clin Transl Med. 2021;11(8):e493.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Morrissey SM, Zhang F, Ding C, et al. Tumor-derived exosomes drive immunosuppressive macrophages in a pre-metastatic niche through glycolytic dominant metabolic reprogramming. Cell Metab. 2021;33(10):2040-2058 e10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Wang M, Qin Z, Wan J, et al. Tumor-derived exosomes drive pre-metastatic niche formation in lung via modulating CCL1(+) fibroblast and CCR8(+) Treg cell interactions. Cancer Immunol Immunother. 2022;71(11):2717–30.

    Article  CAS  PubMed  Google Scholar 

  92. Yin X, Zeng W, Wu B, et al. PPARalpha inhibition overcomes tumor-derived Exosomal lipid-induced dendritic cell dysfunction. Cell Rep. 2020;33(3):108278.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Dang XTT, Kavishka JM, Zhang DX, Pirisinu M, Le MTN. Extracellular vesicles as an efficient and versatile system for drug delivery. Cells. 2020;9(10):2191.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Pantel K, Alix-Panabieres C. Liquid biopsy and minimal residual disease - latest advances and implications for cure. Nat Rev Clin Oncol. 2019;16(7):409–24.

    Article  CAS  PubMed  Google Scholar 

  95. Nakamura Y, Taniguchi H, Ikeda M, et al. Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. Nat Med. 2020;26(12):1859–64.

    Article  CAS  PubMed  Google Scholar 

  96. Sun N, Lee YT, Zhang RY, et al. Purification of HCC-specific extracellular vesicles on nanosubstrates for early HCC detection by digital scoring. Nat Commun. 2020;11(1):4489.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Vitale I, Shema E, Loi S, Galluzzi L. Intratumoral heterogeneity in cancer progression and response to immunotherapy. Nat Med. 2021;27(2):212–24.

    Article  CAS  PubMed  Google Scholar 

  98. Mathieu M, Nevo N, Jouve M, et al. Specificities of exosome versus small ectosome secretion revealed by live intracellular tracking of CD63 and CD9. Nat Commun. 2021;12(1):4389.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Zhang H, Freitas D, Kim HS, et al. Identification of distinct nanoparticles and subsets of extracellular vesicles by asymmetric flow field-flow fractionation. Nat Cell Biol. 2018;20(3):332–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Navarro A, Molins L, Marrades RM, et al. Exosome analysis in tumor-draining pulmonary vein identifies NSCLC patients with higher risk of relapse after curative surgery. Cancers (Basel). 2019;11(2):249.

    Article  CAS  PubMed  Google Scholar 

  101. Kucharzewska P, Christianson HC, Welch JE, et al. Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. Proc Natl Acad Sci U S A. 2013;110(18):7312–7.

    Article  PubMed  PubMed Central  Google Scholar 

  102. Melo SA, Luecke LB, Kahlert C, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. 2015;523(7559):177–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Roberg-Larsen H, Lund K, Seterdal KE, et al. Mass spectrometric detection of 27-hydroxycholesterol in breast cancer exosomes. J Steroid Biochem Mol Biol. 2017;169:22–8.

    Article  CAS  PubMed  Google Scholar 

  104. Fabris L, Calin GA. Circulating free xeno-microRNAs - The new kids on the block. Mol Oncol. 2016;10(3):503–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Ye SB, Li ZL, Luo DH, et al. Tumor-derived exosomes promote tumor progression and T-cell dysfunction through the regulation of enriched exosomal microRNAs in human nasopharyngeal carcinoma. Oncotarget. 2014;5(14):5439–52.

    Article  PubMed  PubMed Central  Google Scholar 

  106. Eichelser C, Stuckrath I, Muller V, et al. Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients. Oncotarget. 2014;5(20):9650–63.

    Article  PubMed  PubMed Central  Google Scholar 

  107. Zhou W, Fong MY, Min Y, et al. Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell. 2014;25(4):501–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  108. Camacho L, Guerrero P, Marchetti D. MicroRNA and protein profiling of brain metastasis competent cell-derived exosomes. PLoS One. 2013;8(9):e73790.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  109. Shao H, Zhang Y, Yan J, et al. Upregulated MicroRNA-483-3p is an early event in pancreatic ductal adenocarcinoma (PDAC) and as a powerful liquid biopsy biomarker in PDAC. Onco Targets Ther. 2021;14:2163–75.

    Article  PubMed  PubMed Central  Google Scholar 

  110. Zheng Y, Campbell EC, Lucocq J, Riches A, Powis SJ. Monitoring the Rab27 associated exosome pathway using nanoparticle tracking analysis. Exp Cell Res. 2013;319(12):1706–13.

    Article  CAS  PubMed  Google Scholar 

  111. Li Y, Zhao Z, Liu W, Li X. SNHG3 Functions as miRNA sponge to promote breast cancer cells growth through the metabolic reprogramming. Appl Biochem Biotechnol. 2020;191(3):1084–99.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  112. Wan L, Xia T, Du Y, et al. Exosomes from activated hepatic stellate cells contain GLUT1 and PKM2: a role for exosomes in metabolic switch of liver nonparenchymal cells. FASEB J. 2019;33(7):8530–42.

    Article  CAS  PubMed  Google Scholar 

  113. Chalmin F, Ladoire S, Mignot G, et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest. 2010;120(2):457–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  114. Lima LG, Chammas R, Monteiro RQ, Moreira ME, Barcinski MA. Tumor-derived microvesicles modulate the establishment of metastatic melanoma in a phosphatidylserine-dependent manner. Cancer Lett. 2009;283(2):168–75.

    Article  CAS  PubMed  Google Scholar 

  115. Xie X, Nie H, Zhou Y, et al. Eliminating blood oncogenic exosomes into the small intestine with aptamer-functionalized nanoparticles. Nat Commun. 2019;10(1):5476.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. Huang L, Rong Y, Tang X, et al. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer. Mol Cancer. 2022;21(1):45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  117. Zhu D, Zhang T, Li Y, et al. Tumor-derived exosomes co-delivering aggregation-induced emission luminogens and proton pump inhibitors for tumor glutamine starvation therapy and enhanced type-I photodynamic therapy. Biomaterials. 2022;283:121462.

    Article  CAS  PubMed  Google Scholar 

  118. Pan S, Zhang Y, Natalia A, et al. Extracellular vesicle drug occupancy enables real-time monitoring of targeted cancer therapy. Nat Nanotechnol. 2021;16(6):734–42.

    Article  CAS  PubMed  Google Scholar 

  119. Moller A, Lobb RJ. The evolving translational potential of small extracellular vesicles in cancer. Nat Rev Cancer. 2020;20(12):697–709.

    Article  CAS  PubMed  Google Scholar 

Download references


Not applicable.


No funders.

Author information

Authors and Affiliations



All authors contributed to the conception and the main idea of the work. XF and JS wrote the original draft and prepared Figs. 1 and 2. B.M.D prepared Table 1. JL, WY and WW reviewed and edited the manuscript; project administration. All authors have read and agreed to the published version of the manuscript.

Corresponding authors

Correspondence to Bradley M. Downs, Weixing Wang or Juanjuan Li.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fu, X., Song, J., Yan, W. et al. The biological function of tumor-derived extracellular vesicles on metabolism. Cell Commun Signal 21, 150 (2023).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: